<DOC>
	<DOC>NCT00353678</DOC>
	<brief_summary>The purpose of this study is to find the best possible (optimal) dose (effect versus adverse events) of YM150 to prevent the risk of blood clot formation after scheduled hip replacement surgery.</brief_summary>
	<brief_title>Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2)</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Darexaban</mesh_term>
	<mesh_term>Factor Xa Inhibitors</mesh_term>
	<criteria>Scheduled for elective primary hip replacement Age 18 years or over Written informed consent obtained Documented history or considered at increased risk of venous thromboembolism Subjects considered at increased risk of bleeding Surgery planned for contralateral hip at the same time or within 10 weeks after enrolment Concomitant use of anticoagulants/ antiplatelet agents</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Hip replacement</keyword>
	<keyword>Arthroplasty</keyword>
	<keyword>Prevention</keyword>
	<keyword>Thromboembolism</keyword>
	<keyword>Treatment outcomes</keyword>
	<keyword>Arthroplasty, replacement, hip</keyword>
</DOC>